RxDoctor Payments Data

Saima Khan, MD

Internal Medicine · Flemington, NJNPI 1881890416

Payments from drug & device makers

$11,189in general payments, 2019–2025

Across 698 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$973
  • Corcept Therapeutics$839
  • Amgen$806
  • AstraZeneca$597
  • Boehringer Ingelheim$533
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,95898%
  • Education$2312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk87$1,176
Lilly USA, LLC64$973
Corcept Therapeutics53$839
Amgen(2 entities)51$806
AstraZeneca(2 entities)40$597
Boehringer Ingelheim34$533
Dexcom, Inc.24$479
Amneal Pharmaceuticals LLC27$407
Mannkind Corporation26$401
Sanofi-aventis U.S. LLC25$393
Abbott20$387
Insulet Corporation19$334
Antares Pharma, Inc.16$256
Tandem Diabetes Care, Inc.9$246
Xeris Pharmaceuticals, Inc.16$243
Pfizer15$242
Bayer12$225
Amarin Pharma, Inc.14$202
Recordati_rare_diseases_inc.11$194
Merck13$174
AbbVie13$163
Astellas Pharma US Inc6$150
Radius Health, Inc.7$131
Currax Pharmaceuticals LLC9$131
Cequr Corporation4$114
Medtronic(2 entities)6$114
IBSA Pharma Inc.7$100
Acella Pharmaceuticals, LLC4$76
BETA Bionics, Inc.2$65
Madrigal Pharmaceuticals3$61
Novartis3$60
Johnson & Johnson4$56
BD4$53
Takeda Pharmaceuticals U.S.A., Inc.3$46
Lifescan, Inc.3$44
Esperion Therapeutics, Inc.3$44
Zealand Pharma US, Inc.3$44
Shire North American Group Inc3$41
Strongbridge US Inc.1$41
Kowa Pharmaceuticals America, Inc.3$40
Neurocrine Biosciences, Inc.2$36
Sequel Med Tech, LLC2$35
Ascendis Pharma Endocrinology Inc2$34
Tolmar, Inc.2$34
Valeritas, Inc.2$33
Companion Medical, Inc.2$33
Intuity Medical Inc2$32
Embecta Corp.2$31
Regeneron Healthcare Solutions, Inc.2$29
Ipsen Biopharmaceuticals, Inc2$27
Topcon Healthcare Solutions, Inc.1$27
Eisai Inc.1$20
Soleno Therapeutics, Inc.1$17
Kyowa Kirin, Inc.1$17
Vivus LLC1$16
Ultragenyx Pharmaceutical Inc.1$15
Nalpropion Pharmaceuticals LLC1$15
Acerus Pharmaceuticals Corporation1$14
Sanofi Pasteur Inc.1$14
Clarus Therapeutics Inc.1$13

How this compares

$11,189 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$126,451
Medicare patients
389
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide377$610,330
JardianceEmpagliflozin313$356,790
JanuviaSitagliptin Phosphate189$211,990
FarxigaDapagliflozin Propanediol141$155,515
MounjaroTirzepatide95$146,838
TrulicityDulaglutide102$145,771
ProliaDenosumab57$99,473
RybelsusSemaglutide58$78,659
Humulin R U-500 KwikpenInsulin Regular, Human48$64,997
TymlosAbaloparatide20$53,494
Evenity (2 Syringes)Romosozumab-Aqqg18$41,412
VascepaIcosapent Ethyl62$39,109
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$35,389
Xigduo XrDapaglifloz Propaned/Metformin23$34,157
Janumet XrSitagliptin Phos/Metformin Hcl36$33,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,176$693,838447 claims
Boehringer IngelheimJardiance, Tradjenta$533$377,207344 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$973$302,934222 claims
MerckJanuvia, Janumet Xr$174$245,728225 claims
AstraZenecaFarxiga$597$155,515141 claims
AmgenProlia, Evenity (2 Syringes)$806$140,88675 claims
Radius Health, Inc.Tymlos$131$53,49420 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$393$30,43324 claims
AbbVieSynthroid$163$26,331237 claims
Johnson & JohnsonInvokana$56$17,45416 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$407$4,922457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →